XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Accounts and Notes Receivable (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]            
Accounts Receivable - trade [1] $ 5,168 $ 5,248 $ 5,168 $ 5,248 $ 4,210  
Notes receivable - trade [1],[2] 1,220 1,327 1,220 1,327 119  
Other [3] 1,227 1,380 1,227 1,380 1,159  
Accounts and notes receivable - net 7,615 7,955 7,615 7,955 5,488  
Accounts Receivable, Allowance for Credit Loss, Current 188 206 188 206 205 $ 194
Amounts due from nonconsolidated affiliates 152 139 152 139 131  
Factoring Agreement [Member]            
Accounts, Notes, Loans and Financing Receivable [Line Items]            
Trade Receivables Sold 49 35 67 43    
Trade receivables sold the remain outstanding with an element of recourse $ 9 $ 17 $ 9 $ 17 $ 2  
[1] Accounts and notes receivable - trade are net of allowances of $188 million, $205 million and $206 million at June 30, 2024, December 31, 2023 and June 30, 2023, respectively.
[2] Notes receivable – trade primarily consists of receivables for deferred payment loan programs for the sale of seed and chemical products to customers. These loans have terms of one year or less and are primarily concentrated in North America. The company maintains a rigid approval process for extending credit to customers in order to manage overall risk and exposure associated with credit losses. As of June 30, 2024, December 31, 2023 and June 30, 2023, there were no significant impairments related to current loan agreements.
[3] Other includes receivables in relation to indemnification assets, royalties, value added tax, general sales tax and other taxes. No individual group represents more than 5 percent of total current assets. In addition, Other includes amounts due from nonconsolidated affiliates of $152 million, $131 million and $139 million as of June 30, 2024, December 31, 2023 and June 30, 2023, respectively.